Oramed Pharmaceuticals Inc.

NasdaqCM:ORMP 株式レポート

時価総額:US$94.3m

Oramed Pharmaceuticals 過去の業績

過去 基準チェック /26

Oramed Pharmaceuticalsは13.2%の年平均成長率で業績を伸ばしているが、Pharmaceuticals業界はgrowingで1.2%毎年増加している。売上は減少しており、年平均17.9%の割合である。

主要情報

13.2%

収益成長率

24.9%

EPS成長率

Pharmaceuticals 業界の成長6.0%
収益成長率-17.9%
株主資本利益率2.8%
ネット・マージンn/a
前回の決算情報30 Sep 2024

最近の業績更新

Recent updates

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Aug 24
Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

May 03
Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Dec 22
Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Oramed: Oral Insulin For Type 2 Diabetes May Become A Reality

Sep 21

Oramed to hand Korean rights for insulin capsule

Sep 09

Oramed to report early-stage trial data for oral COVID-19 shot in 3Q

Jul 07

Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?

Jun 12
Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?

Oramed And Oral Insulin: Can This Small Company Really Do It?

Apr 14

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Feb 23
Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Oramed And The Hurdles Of Developing Oral Insulin

Dec 23

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Nov 02
Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Oramed: Prospects Still Remain Despite Merck-Ridgeback's Progress

Oct 04

We Think Shareholders Will Probably Be Generous With Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Compensation

Aug 24
We Think Shareholders Will Probably Be Generous With Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Compensation

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

Jul 21
Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

Oramed reaches 50% enrollment in late-stage oral insulin study

Jun 08

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

Apr 06
Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

収支内訳

Oramed Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqCM:ORMP 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Sep 240467
30 Jun 2402185
31 Mar 2411086
31 Dec 231689
30 Sep 232-16914
30 Jun 233-201119
31 Mar 233-301126
31 Dec 223-371628
30 Sep 223-462032
30 Jun 223-461933
31 Mar 223-401827
31 Dec 213-351327
30 Nov 213-25822
31 Aug 213-22621
31 May 213-18418
28 Feb 213-15415
31 Dec 203-22521
30 Nov 203-15414
31 Aug 203-12410
31 May 203-1149
29 Feb 203-13411
30 Nov 193-13411
31 Aug 193-14414
31 May 193-15414
28 Feb 193-15414
30 Nov 183-14414
31 Aug 182-13412
31 May 182-12412
28 Feb 182-10310
30 Nov 172-10310
31 Aug 172-10310
31 May 172-13211
28 Feb 172-13210
30 Nov 161-1128
31 Aug 161-1128
31 May 160-836
29 Feb 160-836
30 Nov 150-835
31 Aug 150-735
31 May 150-734
28 Feb 150-734
30 Nov 140-634
31 Aug 140-633
31 May 140-523
28 Feb 140-423

質の高い収益: ORMP 非現金収入 のレベルが高いです。

利益率の向上: ORMP過去に利益を上げました。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: ORMP過去 5 年間で収益を上げており、収益は年間13.2%増加しています。

成長の加速: ORMPは昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。

収益対業界: ORMP昨年収益を上げたため、昨年の収益成長をPharmaceuticals業界 ( 54.6% ) と比較することは困難です。


株主資本利益率

高いROE: ORMPの 自己資本利益率 ( 2.8% ) は 低い とみなされます。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘